Accelerated ApprovalInteresting, another Phase II (so smaller than a phase III), and then apply for accelerated approval..
So Noteable, the first time ONCY has specifically mentioned AA... that's a positive. The downside of course is how long it will take to get the data to run the study... Given that they haven't acknowledged submission of a CTA. I would expect ONCY to be in a position to apply for accelerated approval in mid 2026. If then approved late 2026/early 2027, they would be able to market Pela (with realtime Phase IV trial). Pity they only have cash till early 2025...
look out for dilution.